Biological evaluation of novel 6-Arylbenzimidazo [1,2-c] quinazoline derivatives as inhibitors of LPS-induced TNF- alpha secretion

dc.creator	GALARCE,GLORIA D
dc.creator	FONCEA,ROCÍO E
dc.creator	EDWARDS,ANA M
dc.creator	PESSOA-MAHANA,HERNÁN
dc.creator	PESSOA-MAHANA,CARLOS D
dc.creator	EBENSPERGER,ROBERTO A
dc.date	2008-01-01
dc.date.accessioned	2019-05-02T21:21:43Z
dc.date.available	2019-05-02T21:21:43Z
dc.identifier	https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0716-97602008000100006
dc.identifier.uri	http://revistaschilenas.uchile.cl/handle/2250/81849
dc.description	This study describes the effect of novel 6-Arylbenzimidazo [1,2-c] quinazoline derivatives as tumor necrosis factor alpha (TNF-á) production inhibitors. The newly synthesized compounds were tested for their in vitro ability to inhibit the lipolysaccharide (LPS) induced TNF-á secretion in the human promyelocytic cell line HL-60. The compound 6-Phenyl-benzimidazo [1,2-c] quinazoline, coded as Gl, resulted as the most potent inhibitor and with no significant cytotoxic activity. Thus, 6-Arylbenzimidazo [1,2-c] quinazoline derivatives may have a potential as anti-inflammatory agents
dc.format	text/html
dc.language	en
dc.publisher	Sociedad de Biología de Chile
dc.relation	10.4067/S0716-97602008000100006
dc.rights	info:eu-repo/semantics/openAccess
dc.source	Biological Research v.41 n.1 2008
dc.subject	anti-inflammatory agents
dc.subject	benzimidazoquinazoline derivatives
dc.subject	TNF-á inhibitors
dc.title	Biological evaluation of novel 6-Arylbenzimidazo [1,2-c] quinazoline derivatives as inhibitors of LPS-induced TNF- alpha secretion